On September 19, 2017 Spring Bank Pharmaceuticals, Inc. (NASDAQ:SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and certain cancers, reported a planned poster presentation highlighting recent preclinical data for the next-generation STING (STimulator of INterferon Genes) agonist, SB 11285, at the AACR (Free AACR Whitepaper) Conference on Tumor Immunology and Immunotherapy in Boston, MA (Press release, Spring Bank Pharmaceuticals, SEP 19, 2017, View Source [SID1234520569]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details of the presentation are as follows:

Title: Pharmacodynamic and preclinical studies of SB 11285, a highly potent, and systemically bioavailable STING agonist as a novel immunotherapeutic agent
Date: Monday, October 2, 2017 (Poster Session A)
Time: 5:30 p.m. to 7:30 p.m.
Location: Boston Marriott Copley Place, Boston, MA

About the AACR (Free AACR Whitepaper) Special Conference on Tumor Immunology and Immunotherapy
The conference will highlight recent advances in understanding the range of immune responses towards cancer and how these can be modified and harnessed for prevention and therapeutics. This year’s program will focus on mechanisms, models, and novel technologies all geared towards a deeper understanding of the immunologic science of the cancer cell in order to design better treatments. The conference will take place October 1-4 at the Boston Marriott Copley Place, Boston, MA.